Parexel discusses transdermal drug delivery techs

By Natalie Morrison

- Last updated on GMT

Related tags: Pharmacology

Electroporation is the wave of the future for transdermal drug delivery, according to Parexel’s Ravi Harapanhalli.

The contract research organisation’s (CRO) principle consultant for late stage development told in-PharmaTechnologist that, with recent developments, it is an exciting time for delivery via the skin.

“The industry is at a stage where hydrophilic drugs, peptides, heparin fragments and even proteins can be delivered through the skin,”​ said Harapanhalli.

“This is a big development in the design and control of drugs.”

Put to Harapanhalli the question of the next ‘big thing’ in the research area, he said that electroporation shows promise.

He added: “I must say electroporosis – passage of low voltage electric current through the patch (is promising).

“The method is commonly used in development at the moment, and there are some approved products already using that technology and they are able to achieve better controlled and more effective delivery.”

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

lyo_development

Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

Related suppliers

Follow us

Products

View more

Webinars